The MassARRAY SARS-CoV-2 Panel is a high-throughput and low-cost assay designed for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens and bronchoalveolar lavage (BAL) from individuals suspected of COVID-19 by their healthcare provider. The assay for in vitro diagnostic use has received FDA Emergency Use Authorization (EUA) and is CE-IVD marked for in vitro diagnostic use in Europe. Request Information
• ACCURATE DETECTION: Five SARS-CoV-2 assays multiplexed into a single reaction, targeting the nucleocapsid (N) gene and ORF1ab region.
• SCALABLE THROUGHPUT: Process up to thousands of samples per day with a single instrument.
• LOW COST: Low-cost reagents and automated results reporting saves lab resources.
• RELIABLE SUPPLY: Overcome instrument and reagent shortages with a reliable supply. Request Information